Pricing
  1. US-listed companies
  2. Edesa Biotech, Inc.
  3. Financials
  4. Stock-based compensation

Edesa Biotech, Inc.【EDSA】

Market cap
$35.96M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Sep 30, 20241-56.88%
Sep 30, 20231-44.86%
Sep 30, 20222-29.26%
Sep 30, 20213+434.04%
Sep 30, 20201+287.76%
Sep 30, 20180+33.55%
Sep 30, 20170-55.45%
Sep 30, 20160-2.94%
Sep 30, 20150

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)